Venlo, Netherlands — May 6, 2026 — Leads & Copy — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) reported its full first-quarter results for 2026, aligning with the preliminary announcement. The company demonstrated strong profitability, with adjusted diluted earnings per share (EPS) meeting expectations. However, sales trends were mixed, as declines in QuantiFERON sales and cautious U.S. Life Sciences customer demand offset growth in other parts of the portfolio.
Net sales for Q1 2026 increased by 2% on a reported basis to $492 million. Sales at constant exchange rates (CER) decreased by 1%, compared to the outlook for at least 1% CER growth, as announced on April 27. Adjusted diluted EPS CER of $0.54 was in line with the outlook for at least $0.54 CER.
QIAGEN’s growth pillars collectively grew 4% CER compared to Q1 2025. Sample technologies experienced a 9% CER increase, or 3% CER excluding the Parse acquisition, driven by demand for automated consumables and instrument placements. QIAcuity digital PCR saw double-digit CER sales growth due to higher consumables and instrument sales year-over-year. QIAGEN Digital Insights (QDI) recorded single-digit gains led by clinical bioinformatics. QIAstat-Dx sales decreased by 1% CER, as anticipated, due to challenging prior-year results. However, QIAstat-Dx consumables sales increased, despite a weaker respiratory season, driven by double-digit CER growth from the recently launched Gastrointestinal and Meningitis panels in the U.S. QIAstat-Dx instrument placements remained at a good level.
QuantiFERON sales declined 5% CER from Q1 2025, primarily due to a significant decrease in immigration testing demand in the United States and the Middle East. Trends in other patient testing groups remained solid. QIAGEN now anticipates full-year 2026 QuantiFERON sales to remain unchanged at CER compared with 2025 sales of $503 million.
QIAGEN updated its full-year 2026 outlook on April 27, projecting net sales to grow about 1-2% CER (previously at least 5% CER growth). This revision is attributed to headwinds from reduced QuantiFERON immigration testing demand, ongoing caution among U.S. Life Sciences customers, and increased geopolitical uncertainty. Adjusted diluted EPS are now expected to be at least $2.43 CER (previously at least $2.50 CER).
According to Thierry Bernard, Chief Executive Officer of QIAGEN, the company made significant progress across various areas of its portfolio in the first quarter, driven by strong sales growth in Sample technologies, QIAcuity, and QIAGEN Digital Insights. While QuantiFERON was affected by a decline in immigration testing demand, Bernard views this as a rebasing of demand within this testing group during 2026 rather than a shift in the long-term potential for latent TB testing. The company is focused on achieving its updated 2026 targets and positioning itself for faster growth in the second half of the year.
Roland Sackers, Chief Financial Officer of QIAGEN, stated that the company’s first-quarter profitability reflected disciplined execution in a challenging environment. QIAGEN managed the impact of supporting portfolio investments, as well as headwinds from tariffs, currency movements, and measures to ensure reliable product supply. The company is focused on delivering profitable growth through efficiency gains, disciplined capital allocation, and targeted investments to strengthen its long-term growth potential and create value for shareholders.
QIAGEN plans to host a virtual Spotlight Session on May 7, 2026, to provide insights into its strategic priorities for QuantiFERON and an update on recent product enhancements. The online event is scheduled for Thursday, May 7, 2026, at 15:30 Frankfurt Time / 14:30 London Time / 9:30 New York Time. Registration details and further information about the webcast are available in the Investor Relations section of the QIAGEN website (www.qiagen.com), under Events and Presentations (https://corporate.qiagen.com/English/investor-relations/events-and-presentations/), with a recording accessible after the event.
QIAGEN N.V., based in the Netherlands, is a global provider of Sample to Insight solutions. Its technologies isolate and process DNA, RNA, and proteins from biological samples. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data. Automation solutions integrate these steps into streamlined workflows. QIAGEN serves over 500,000 customers in Life Sciences and molecular diagnostics worldwide and employed approximately 5,500 people across more than 35 locations as of March 31, 2026.
Source: QIAGEN N.V.
